3.130USD-2.19%Mkt Cap: 24.77M USDP/E: —Last update: 2026-05-26
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid d…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap24.77M USD
Enterprise Value20.42M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-21.79M USD
Revenue/Share—
Last Price3.130 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees11
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS15117F8077
Valuation
P/E (Trailing)—
P/E (Forward)-1.98
PEG—
EV/EBITDA-0.92
EV/Revenue—
P/S—
P/B4.77
EPS (TTM)-5.38
EPS (Forward)-1.60
52W Range
2.4304% of range20.70
52W High20.70 USD
52W Low2.430 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-255.25%
ROA-145.48%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-23.12M USD
CapEx (TTM)5.88K USD
FCF Margin—
FCF Yield-51.60%
Net Debt-6.82M USD
Net Debt/EBITDA0.31
Balance Sheet
Debt/Equity0.05
Current Ratio1.90
Quick Ratio1.71
Book Value/Sh0.6640 USD
Cash/Share1.044 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJul 17, 2018
Splits
Last Split1:30
Split DateJun 24, 2025
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)10.33 USD
Target Range10.00 USD – 11.00 USD
# Analysts3
Ownership
Shares Out.7.99M
Float7.77M
Insiders2.29%
Institutions4.17%
Short Interest
Short Ratio0.8d
Short % Float0.55%
Short % Out.0.54%
Shares Short22.95K
Short (prev mo.)61.20K
Technical
SMA 502.939 (+6.5%)
SMA 2003.655 (-14.4%)
Beta0.43
S&P 52W Chg28.31%
Avg Vol (30d)2.04M
Avg Vol (10d)328.21K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—